Volume 14, Number 2—February 2008
Research
Effectiveness of Personal Protective Measures to Prevent Lyme Disease
Marietta Vázquez*
, Catherine Muehlenbein*, Matthew L. Cartter†, Edward B. Hayes‡, Starr Ertel†, and Eugene D. Shapiro*
, Catherine Muehlenbein*, Matthew L. Cartter†, Edward B. Hayes‡, Starr Ertel†, and Eugene D. Shapiro*
Table 2
Characteristics of Lyme disease study participants, Connecticut, July 2000 through February 2003
| Characteristics | Case-patients (N = 709), no. (%) | Controls (N = 1,128), no. (%) | p value |
|---|---|---|---|
| Age, y | |||
| Median | 48 | 49 | 0.71 |
| Mean | 46 | 47 | |
| Range | 15–70 | 15–70 | |
| Sex | |||
| Female | 376 (53) | 715 (63) | <0.001 |
| Male | 333 (47) | 413 (37) | |
| Race | |||
| Caucasian | 689 (97) | 1094 (97) | 0.66 |
| African American | 3 | 8 | |
| Hispanic | 4 | 6 | |
| Other | 13 | 14 | |
| Underlying medical problems other than Lyme disease (e.g., diabetes, asthma) | 298 (42) | 508 (45) | 0.19 |
| Had Lyme disease* | 110 (17) | 143 (14) | 0.095 |
| Received Lyme vaccine† | 44 (6) | 73 (6) | 0.82 |
*Having Lyme disease was defined as the following: for case-patients, having Lyme disease at a time other than the episode for which a case-patient was enrolled in the study; for controls, having Lyme disease at a time other than the focal time of disease for the case-patient.
†A study participant was considered vaccinated if he or she received at least 1 dose of Lyme vaccine.
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.